API’s Response to Recent TEC Edmonton Announcement


Share this:

For Immediate Release

April 8th, 2021 

Re: Announcement that TEC Edmonton will cease operations effective June 30th, 2021 

Applied Pharmaceutical Innovation (API) wishes to acknowledge TEC Edmonton for their contributions to the innovation ecosystem in Edmonton over the past 15 years. While there are many changes on the horizon as part of the decision to wind down TEC Edmonton over the coming months, API feels confident that there is a bright future for life sciences companies of all stages in the city. 

“We’re building tremendous momentum here in Alberta, and I believe that we’re at a turning point as the sector matures” says API CEO Andrew MacIsaac. “In the weeks and months ahead we look forward to working closely with our colleagues at Innovate Edmonton and the University of Alberta to ensure that we can step up and provide the scale-up capacity for life sciences innovation being nurtured here in Edmonton and across the province.”

Since its launch in 2018, API has rapidly grown as a support system working collaboratively with programs such as TEC Edmonton to provide access to the technical expertise and highly qualified personnel associated with the commercial development of products in the highly-regulated health sector. API’s support enables companies to do their commercial development locally, keeping jobs in-province and continually making the region more attractive for investment. 

In the coming months, API is launching additional supports to provide companies developing intellectual property ranging from pharmaceuticals to natural health products with the capacity to scale and grow within Edmonton.